Benchmark initiated its coverage on Haemonetics Corporation HAE with a Buy rating and a price target of $89 a share.
Benchmark commented, "Haemonetics is positioned to leverage a stable base of mid-single digit organic revenue growth in its blood products management businesses. Organic growth in these core businesses is driven by demographics, emerging market expansion and the proliferation of pharmaceutical applications for plasma that involve rare diseases, such as hemophilia."
Haemonetics Corporation closed at $77.58 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in